Company intelligence / Profile preview

Autem Therapeutics

Hanover, New Hampshire, United Statesautemtherapeutics.com ↗

Ownership: Private
Employees: ~18
Development stage: Preclinical

Overview

Initial clinical feasibility studies involving 66 HCC patients suggest that amplitude modulated EM frequencies may be effective in shrinking cancerous tumors, enhancing quality of life and extending survival in patients with early and advanced stage HCC. The therapy has shown promise with median overall survival (mOS) of 11.5 months and quality of life (QoL) of 14+ months TTD[3][4].

Therapeutic areas: Oncology
Modalities: Bioelectric therapyAmplitude-modulated electromagnetic (EM) frequency
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

AutEMsys

Pre-clinical

Indications: Hepatocellular carcinoma, Solid tumors

Beyond the preview

Go deeper on Autem Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Autem Therapeutics.

Explore the full profile